CABA250117C1000
- 1.20
- 0.000.00%
Cabaletta Bio Newsroom
HC Wainwright & Co. Reiterates Buy on Cabaletta Bio, Maintains $25 Price Target
William Blair Maintains Cabaletta Bio(CABA.US) With Buy Rating
William Blair Remains a Buy on Cabaletta Bio (CABA)
Cabaletta Bio Advances Clinical Trials With Lonza Partnership
Cabaletta Bio Announces Strategic Priorities, Anticipated Milestones for 2025
Express News | Cabaletta Bio Inc: Unaudited Cash and Cash Equivalents as of Dec 31, 2024 Was $164 Mln
Cabaletta Bio Outlines 2025 Milestones, Plans Meeting With FDA On Rese-cel Trial Designs, Favorable Safety With 90% Patients Showing No Significant Side Effects, First Enrollments In RESET-PV And RESET-Myositis Trials, IND Cleared For RESET-MS With...
Express News | Cabaletta Bio Inc - Caballetta to Meet FDA on Rese-Cel Trial Designs in 1H25
Express News | Cabaletta Bio Outlines Strategic Priorities and Anticipated Key Milestones for 2025
Wells Fargo Downgrades Cabaletta Bio(CABA.US) to Hold Rating, Cuts Target Price to $6
Evercore Initiates Cabaletta Bio(CABA.US) With Hold Rating, Announces Target Price $6
Analysts Conflicted on These Healthcare Names: Verastem (VSTM), Roche Holding AG (OtherRHHVF) and Cabaletta Bio (CABA)
BofA Securities Cuts Price Target on Cabaletta Bio to $29 From $31, Keeps Neutral Rating
Cabaletta Bio Cut to In-Line From Outperform by Evercore ISI Group
Evercore ISI Group Downgrades Cabaletta Bio to In-Line, Lowers Price Target to $6
This C3.ai Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday
Cabaletta Bio Analyst Ratings
Wells Fargo Downgrades Cabaletta Bio to Equalweight From Overweight, Cuts Price Target to $6 From $12
Peering Into Cabaletta Bio's Recent Short Interest
Cabaletta Bio, Inc.'s (NASDAQ:CABA) Latest 25% Decline Adds to One-year Losses, Institutional Investors May Consider Drastic Measures